Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized single-centre study

• Published in: Anadolu kardiyoloji dergisi : AKD 2014-06, Vol.14 (4), p.363-369
• Main Authors: Sendur, Mehmet Ali Nahit, Güven, Gülay Sain, Yorgun, Hikmet, Ateş, Ahmet Hakan, Canpolat, Uğur, Sunman, Hamza, Karahan, Sevilay, Kaya, Bariş, Aytemir, Kudret
• Format: Article
• Language: English
• Subjects: Antihypertensive Agents - administration & dosage; Blood Pressure; C-Reactive Protein - metabolism; Humans; Hypertension - blood; Hypertension - diagnosis; Hypertension - drug therapy; Imidazoles - administration & dosage; Male; Middle Aged; Nebivolol - administration & dosage; Nitric Oxide - blood; Plasminogen Activator Inhibitor 1 - blood; Tetrazoles - administration & dosage; Treatment Outcome; Turkey; Vasodilation - drug effects
• ISSN: 1302-8723; 2149-2263; 1308-0032; 2149-2271
• DOI: 10.5152/akd.2014.4793

This study was aimed to investigate the effects of olmesartan or nebivolol treatment on blood pressure and some endothelial function markers in newly diagnosed patients with stage 1 essential hypertension. This randomized open label study included 85 newly diagnosed patients with stage 1 hypertension (50 males, mean age: 52 ± 9 years). Blood pressure, flow mediated vasodilatation (FMD) and echocardiographic measurements of the patients were taken before and 8 weeks after the beginning of treatment with olmesartan or nebivolol. Nitric oxide, plasminogen activator inhibitor 1 (PAI-1) and C reactive protein (CRP) levels measured in serum samples before and after treatment, were compared. Basal variables that can affect the antihypertensive response were evaluated by multivariate logistic regression analysis. The reduction observed in the systolic and diastolic blood pressures after antihypertensive treatment was significant (p